Clinical and Translational Oncology

, Volume 14, Issue 7, pp 541–544 | Cite as

SEOM clinical guidelines for the management of adult soft tissue sarcomas

  • Xavier García del Muro SolansEmail author
  • Javier Martín Broto
  • Pilar Lianes Barragán
  • Ricardo Cubedo Cervera
Clinical Guides in Oncology


Soft tissue sarcomas are uncommon tumors of mesenchimal cell origin. Criteria for suspicion is a soft tissue mass that is increasing in size, and has a size greater than 5 cm or is located under the deep fascia. Diagnosis and management of these patients should preferably be performed by a specialist multidisciplinary team in a referral center. Assessment of a patient with a suspect of sarcoma should include magnetic resonance and biopsy performed prior to surgery. Primary local therapy for patients with localized sarcoma is based on wide surgical resection with a tumor-free tissue margin, in association in most cases with radiotherapy. Adjuvant chemotherapy constitutes an option that could be considered in high-risk sarcomas of the extremities. When metastasis are present, surgery of pulmonary lesions, in some selected patients, and chemotherapy are current available options.


Soft tissue sarcoma Clinical guidelines 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bhangu AA, Beard JA, Grimer RJ (2004) Should soft tissue sarcomas be treated at a specialist centre? Sarcoma 8:1–6PubMedCrossRefGoogle Scholar
  2. 2.
    O'sullivan B, Davis AM, Turcotte R et al (2002) Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 359:2235–2241PubMedCrossRefGoogle Scholar
  3. 3.
    Pervaiz N, Colterjohn N, Farrokhyar F et al (2008) A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113:573–581PubMedCrossRefGoogle Scholar
  4. 4.
    Frustaci S, Gherlinzoni F, De Paoli A et al (2001) Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19:1238–1247PubMedGoogle Scholar
  5. 5.
    Issels RD, Lindner LH, Verweij J et al (2010) neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 11:561–570PubMedCrossRefGoogle Scholar
  6. 6.
    Kim S, Ott HC, Wright CD et al (2011) Pulmonary resection of metastatic sarcoma: prognostic factors associated with improved outcomes. Ann Thorac Surg 92:1780–1786; discussion 1786–1787PubMedCrossRefGoogle Scholar
  7. 7.
    Maurel J, Lopez-Pousa A, de Las Penas R et al (2009) Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol 27:1893–1898PubMedCrossRefGoogle Scholar
  8. 8.
    Demetri GD, Chawla SP, von Mehren M et al (2009) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27:4188–4196PubMedCrossRefGoogle Scholar
  9. 9.
    Garcia-Del-Muro X, Lopez-Pousa A, Maurel J et al (2011) Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 29:2528–2533PubMedCrossRefGoogle Scholar
  10. 10.
    Maki RG, Wathen JK, Patel SR et al (2007) Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25:2755–2763PubMedCrossRefGoogle Scholar
  11. 11.
    Verweij J, Baker LH (2010) Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. Eur J Cancer 46:863–868PubMedCrossRefGoogle Scholar
  12. 12.
    McArthur GA, Demetri GD, van Oosterom A et al (2005) Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23:866–873PubMedCrossRefGoogle Scholar

Copyright information

© FESEO 2012

Authors and Affiliations

  • Xavier García del Muro Solans
    • 1
    Email author
  • Javier Martín Broto
    • 2
  • Pilar Lianes Barragán
    • 3
  • Ricardo Cubedo Cervera
    • 4
  1. 1.Department of Medical Oncology Institut Català d’Oncologia L’Hospitalet Hospital Duran i ReynalsL’Hospitalet de LlobregatBarcelonaSpain
  2. 2.Hospital Son EspasesPalma de MallorcaSpain
  3. 3.Hospital de MataróMataró, BarcelonaSpain
  4. 4.Hospital Puerta de HierroMajadahonda, MadridSpain

Personalised recommendations